Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn's Disease

Vedolizumab subcutaneous is currently under review for approval for ulcerative colitis with the European Medicines Agency EMA and U.S. Food and Drug Administration FDATakeda Pharmaceutical Company Limited TSE4502NYSETAK Takeda today announced topline resul...